NCT00143286 - A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation | Biotech Hunter

Enrollment

2,000

Participants

Timeline

Start Date

April 30, 2003

Study Completion Date

March 31, 2005

Conditions

Smoking Cessation

Interventions

DRUG

varenicline (CP-526,555)

Trial Locations (24)

Pfizer Investigational Site, Santa Ana

Pfizer Investigational Site, West Palm Beach

Pfizer Investigational Site, Lexington

Pfizer Investigational Site, Mogadore

Pfizer Investigational Site, Dallas

Pfizer Investigational Site, Seattle

Pfizer Investigational Site, Calgary

Pfizer Investigational Site, Halifax

Pfizer Investigational Site, Ottawa

Pfizer Investigational Site, Toronto

Pfizer Investigational Site, Cornwall

Pfizer Investigational Site, Sherbrooke

Pfizer Investigational Site, Prague

Pfizer Investigational Site, Hellerup

Pfizer Investigational Site, Aarhus C

Pfizer Investigational Site, Frederikssund

Pfizer Investigational Site, Bergen

Pfizer Investigational Site, Hønefoss

Pfizer Investigational Site, Oslo

Pfizer Investigational Site, Gothenburg

Pfizer Investigational Site, Helsingborg

Pfizer Investigational Site, Stockholm

Pfizer Investigational Site, London